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Toxic Potential of the Plasticizer
Di(2-ethylhexyl) Phthalate in the Context
of Its Disposition and Metabolism
in Primates and Man
by Carl C. Peck* and Phillip W. Albrot
Although human toxicity from exposure to the plasticizer di(2-ethylhexyl) phthalate (DEHP)
is unknown, reports of animal toxicity from DEHP have stimulated extensive toxicological
studies. In the absence ofdirect toxicity data, information on the disposition and metabolism of
DEHP in primates and man may enhance our assessment ofthe toxic potential ofDEHP in man.
Studies of DEHP disposition and metabolism in the African Green monkey and man show that
the compound is rapidly and extensively metabolized. It is excreted largely in the urine (> 90%o)
asconjugated(glucuronide)oxidationproductsofmono(2-ethylhexyl)phthalate;excretioninfeces
accounts for the other 10% of the administered DEHP. Plasma disappearance of parenterally
administeredDEHPisequallyrapidsothatby24hrfollowingDEHPadministration, plasmaDEHP
concentrations arevirtually undetectable, whilegreaterthan 70oofthedose has beenexcreted in
urine andstool. Thetransience ofDEHP in primates andtheextenttowhich it is metabolizedand
conjugated may play a role in the observed lack oftoxicity.
Introduction
Interest in the toxic potential of the principal
plasticizer contaminant of blood storage, di(2-
ethylhexyl) phthalate (DEHP), was kindled by
reports of DEHP residues in tissues of patients
receiving stored blood products (1). However, dis-
covery of DEHP in tissues of humans who had not
received transfusions (2), serious disagreement
between research laboratories on results of assay
determinations of DEHP in identical aliquots of
DEHP-spiked tissue samples (3), and frequent
assay contamination withubiquitous environmental
DEHP (4), all have made reports of DEHP detec-
tion in human tissues difficult to interpret.
Potential DEHP toxicity has been inferred from
numerous animal studies. However, many studies
of the toxicity of DEHP in animals have entailed
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nonintravenous routes of administration, atypical
dosage formulations, and excessive doses which do
not imitate the exposure pattern in man (5-7).
Correspondingly, the relevance of such studies to
human parenteral exposure at relatively low doses
ofprotein-bound DEHP in stored blood products is
not amenable to rigorous scientific scrutiny at
present. Two exceptions to this criticism bear
mention. Garvin et al. (8) reported that no acute or
cumulative toxicity could be demonstrated in rats
infused twice weekly for 9 weeks with DEHP-rich
stored homologous plasma. Each infusion resulted
in a DEHP dosage which was equivalent to that
which a human adult would receive from a 12-unit
wholebloodtransfusion. Ontheotherhand,Jacobson
and co-workers (9) attributed hepatotoxicity to
DEHP in rhesus monkeys given weekly autologous
infusions of DEHP-rich platelet concentrates for 1
year. The DEHP infused each week was roughly
equivalent to that a human would receive from a
2-unit whole blood transfusion. Whether these
investigators correctly interpreted their results as
DEHP toxicity is uncertain, since the exposure
levels of mono(2-ethylhexyl) phthalate (MEHP)12
were notreported (seediscussion onthesignificance
ofMEHP below). The importance ofpaying careful
attention to the details of comparable dosage, the
physical state of the dosing formulation and its
composition in the planning and interpretation of
DEHP toxicity studies has been emphasized (10).
Although humantoxicity to DEHPthrough blood
transfusions hasnotbeendocumented, thereremains
a concern for the potential toxicity of this ubiqui-
tous compound. In the absence of direct clinical
toxicity data, the potential for various effects may
be evaluated from knowledge oftissue distribution,
the chemical nature of DEHP metabolites and
conjugates, the organs involved in DEHP metabo-
lism and elimination, and the time course of these
phenomena. It is in this context that we review
current knowledge of the disposition and metabo-
lism of DEHP in primates and man.
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Studies performed in our laboratory and else-
where (14-16)indicatethatplasmaDEHPundergoes
hydrolysis to MEHP during storage, presumably
under the influence of plasma nonspecific lipase.
This reaction results in accumulation of MEHP in
whole blood (0.8-2.9 mg/unit after 21 days of stor-
age), as well as in platelet concentrates (0.82
mg/platelet pack after 50 hr ofstorage). Interest in
MEHP stems from evidence indicating that large
oraldosesofMEHP arehepatotoxicinrodents (17).
African Green Monkey Studies
We initiated our investigation of the disposition
of DEHP in primates by studying the distribution,
elimination, and metabolism of this compound in
the African Green monkey (11-13, 18). In order to
Structure and Leaching of DEHP
The chemical structure of DEHP is shown as I.
DEHP consists of a benzene ring to which are
attached two carboxyl groups. Each ofthe latter is
coupled to a 2-ethylhexanol side chain by an ester
bond. The asterisk on the carbonyl carbon indicates
the position of a 14-C label which was used in our
studies of the disposition of DEHP in the primate
African Green monkey (11-13). Either carbonyl
carbon may be the site at which plasma and tissue
esterases in primates act to cleave one of the
2-ethylhexanol side chains to produce MEHP.
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DEHP is a clear, oily liquid which is highly
fat-soluble and poorly water-soluble. In poly(vinyl
chloride) (PVC) blood storage containers, the plas-
ticizer resides in the PVC matrix as a semisolid and
readily migrates from the plastic into plasma dur-
ing storage. DEHP accumulates in plasma during
4°C liquid whole blood storage at a rate of approx-
imately 1 mg/unit/day and 6 mg/unit of platelet
concentrate/day during storage at room tempera-
ture (14).
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FIGURE 1. Plasma 14C concentrations in three African Green
monkeys (AG 1, 2, 4) following bolus injection of 14C-DEHP
leached into autogolous plasma. The solid line running
through the data (x) was generated from a computer fit of
the data (13).
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xDEHP DISPOSITION IN PRIMATES AND MAN
simulatecloselythemannerinwhichmanisexposed
to DEHP when receiving blood products, we pro-
cured a strip ofPVC plastic (Fenwal Laboratories,
Morton Grove, Ill.) which was impregnated with
14C-DEHP. This sheet exhibited physical charac-
teristics which were identical to that of Fenwal's
PL-146 blood bag plastic. A 20-ml aliquot ofplasma
was taken from each of three African Green mon-
keys; PVC strips containing 14C-DEHP were im-
mersed in these plasmas and stored at 4°C forup to
5 months. At the time ofreinfusion, these plasmas
each contained around 3 mg of 14C-DEHP, which
was equivalent to that in a two-unit infusion of
21-day-old bank blood in a human. Thin-layer
chromatography (TLC) and gas chromatography
mass-spectrometry (GC-MS) analysis (18) ofone of
the incubated plasmas revealed the '4C to be
distributed as 96% 14C-DEHP and 4% 14C-MEHP:
this pattern closely resembles that of unlabeled
phthalates in human plasma stored in conventional
PL-146 blood bags. Following bolus infusion ofthe
14C-DEHP-laden autologous plasma, serial plasma,
urine and stool samples were obtained and counted
for 14C activity.
As canbe seenin Figure 1, plasma14C concentra-
tion rapidly declined, so that by 90 min after
infusion there was less than 5%, and after 12 hr
there was less than 1% ofthe initial 14C concentra-
tion. Characterization ofthe chemical structures of
the 14C compounds inplasmaduringthe first 30min
after infusion, revealed rapid conversion of DEHP
to MEHP and more fully oxidized MEHP deriva-
tives (Fig. 2).
Figure 3 shows the buildup of '4C in urine
following the infusion. It can be seen that by 4 hr
after infusion, greater than 50% ofinjected 14C had
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been excreted in the urine, and that by 24 hr,
greater than 70% had been excreted by the kid-
neys.
Table 1 reveals the chemical structure of DEHP
metabolites in urine of the African Green monkey
as identified by GC-MS (18). The predominant
metabolites were the 5-ethyl, isohexanol monoester
of phthalic acid and MEHP. More than 80% of
urinary metabolites were conjugated to glucuron-
ide. The cumulative urinary excretion patterns of
DEHP metabolites during the first 4 hr are plotted
in Figure 4.
Fecal 14C excretion accounted for up to 8% ofthe
injected 14C by 48 hr after infusion (Fig. 5). The
theoretical cumulative urinary excretion of 14C at
infinite time (beyond 4-5 days) coupled with the
measured fecal excretion of 4C accounted for the
entire injected dose of 14C-DEHP.
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FIGURE 2. Plasma DEHP and metabolites ofDEHPduringthe
first 30 min following injection of "C-DEHP leached into
autologous African Green monkey plasma (13).
FIGURE 3. Cumulative 14C excretion in urine ofthree African
Greenmonkeysfollowingbolusinjectionof14C-DEHPleached
into autologous plasma. The solid line running through the
data (x) was generated from a computer fit ofthe data (13).
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-XTable 1. DEHP metabolites in urine of an African Green monkey (AG#4).
Metabolite
Code Ra % of dose 4 hr after infusion
12 B CH2-CH(C2H5)-(CH2)2-CHOH-CH3 26.1
MEHP CH2-CH(C2H5)-(CH2)3-CH3 19.6
Unhydrolyzedb 5.4
11 CH2-CH(CH2CH20H)-(CH2)3-CH3 3.2
10 CH2-CH(C2H5)-(CH2)2-CO-CH3 3.1
11 X CH2-CH(C2H5)-(CH2)-CHOH-CH2-CH3 2.7
9 E CH2-CH(C2H5)-(CH2)3-COOH 2.7
DEHPC CH2-CH(C2H5)-(CH2)3-CH3c <1.8
9 A CH2-CH(C2H5)-(CH2)-COOH Trace
9 C CH2-CH(C2H5)-(CH2)2-COOH Trace
13 B CH2-CH(C2H5)-(CH2)3-CH20H Trace
Phthalic acid H Trace
Total 66.9
aStructure: o-C6H4 (COOX)COOR, where X = glucuronide or H.
bBy 0-glucuronidase or sulfatase.
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FIGURE 4. Cumulative excretion of individual DEHP metabolites in urine of one African Green monkey (AG 4) following bolus
injection of 14C-DEHP in autologous monkey plasma. The metabolite codes are the same as those in Table 1.
DEHP Disposition and
Metabolism in Man
A detailed study of the disposition and metabo-
lism of DEHP in two cancer patients receiving
larger doses of DEHP via platelet concentrate
infusions has been reported (13, 19). One patient
(case I) received 94.7 mg of DEHP in 4 hr, and
another (case II) received 174.3 mg ofDEHP in 1.5
hr. Figure 6 shows the cumulative urinary excre-
tion ofall DEHP derivatives. More than 50% ofthe
infused dose appeared as DEHP derivatives in
urine within 6 hr. This pattern is similar to that
seen in the African Green monkey (cf. Fig. 3).
Table 2 is a list ofthe chemical structures ofthe
urinary metabolites (case II) which were identified
by GC-MS (18). As in the African Green monkey,
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Table 2. DEHP metabolites in human urine (case II).
Metabolite
Code Ra Cumulative % ofdose 24 hr after infusionb
12 B CH2-CH(C2H5)-(CH2)2-CHOH-CH3 23.4
11 CH2-CH(CH2CH2OH)-(CH2)3-CH3 8.3
10 CH2-CH(C2H5)-(CH2)2-CO-CH3 7.7
MEHP CH2-CH(C2H5)-(CH2)3-CH3 6.9
11-X CH2-CH(C2H5)-CH2-CHOH-CH2-CH3 6.1
9-E CH2-CH(C2H5)-(CH2)3-COOH 4.7
9-D CH2-CH(CH2COOH)-(CH2)3-CH3 1.5
9-B CH2-CH(COOH)-(CH2)3-CH3 1.2
13-B CH2-CH(C2H5)-(CH2)3-CH2OH Trace
Total 59.8c
aStructure: o-C6H4(COOX)(COOR), where X = glucuronide (80%) or H.
bEach is underestimated by < 2% due to sample loss. CUnderestimated by 6.1%.
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FIGURE 5. Cumulative excretion of"4C in stool ofthreeAfrican
Green monkeys (AG 1, 2, 4) following injection of14C-DEHP
in autologous plasma.
TIME (HOURS)
FIGURE 6. Cumulative urinary excretion of total DEHP
metabolites in two cancer patients following platelet concen-
trate infusions containing leached DEHP.
the predominant metabolite was the 5-ethyl, iso-
hexanol monoester ofphthalic acid, but in contrast
to the urinary metabolite pattern in the monkey,
MEHP is fourth on the list and is followed by four
more fully oxidized derivatives ofMEHP. As in the
monkey, approximately 80% ofthe urinary metabo-
lites were conjugated to glucuronide.
Figure 7 shows the cumulative urinary concen-
trations of various DEHP derivatives in case II
throughout the first 24 hr after infusion.
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FIGURE 7. Cumulative urinary excretion ofindividual DEHP metabolites in a cancer patient (case II) following a 1.5-hr infusion of
concentrated platelets containing 174.3 mg ofleached DEHP. The metabolite codes are the same as those in Table 2. Asterisks (*)
denote values underestimated by < 2% due to sample loss.
A study ofthe disappearance of DEHP in human
plasma following infusion of DEHP-laden platelet
concentrates (20) enabled its pharmacokinetic char-
acterization (21). Plasma disappearance half-life
was 30 ± 12 mmn, apparent distribution volume was
2819 ± 383 ml/m2 and clearance was 78 ± 20 ml/
min_M2 (n = 6). Based upon these average pharma-
cokinetic parameters, Figure 8 shows the plasma
DEHP time profile for a simulated platelet infusion
in which 90 mg DEHP in 530 ml of pooled platelet
concentrate is infused in a 30-min period into a
70-kg man. The DEHP is initially distributed into a
volume which is slightly larger than blood volume,
rapidly distributes to other tissues and disappears
from plasma so that it is essentially undetectable 4
hr after infusion.
Discussion
Consideration ofthese kinetic and metabolic data
in the light ofpotential toxicity in humans leads to
some preliminary answers and invites new ques-
tions. The restricted apparent distribution space,
rapid disappearance from plasma, rapid urinary
excretion and extensive hydrolysis, oxidation, and
glucuronide conjugation could all be interpreted as
"detoxification" mechanisms. Such an interpreta-
tion, however, requires knowledge of tissue sensi-
tivitiesto DEHPanditsmetabolites. Intheabsence
of such information, DEHP disposition data con-
tribute to our assessment ofpotential DEHP toxic-
ity in several ways. For instance, the extensive
metabolism and rapid excretion of DEHP metabo-
lites cast serious doubt on the contention that
DEHP found in human tissues is a result of blood
transfusions or exposure from other environmental
sources; contamination during sample preparation
and assay appears to be a more likely explanation.
Moreover, the rapid excretion ofthe bulk ofDEHP
metabolites within 8 hr following infusion of blood
products suggests that DEHP-related toxicity is
more likely to be acute in onset rather than a
late-appearing or long-term effect. Any toxicity
observed may be the effect of a metabolic product
ofDEHP rather than the parent compound. In this
regard, the reports of MEHP accumulation during
blood product storage (14, 15) and description ofits
hepatotoxicity in rodents (17) should focus future
research efforts on this compound in particular.
Moreover, since the enzymes responsible forhydrol-
ysis, oxidationandconjugationofDEHP and MEHP
may be located primarily in the liver, this organ, as
well as the kidney, will be exposed to relatively
high concentrations of DEHP derivatives. This
knowledge should focus DEHP toxicity research on
these two organs, as well as alert investigators to
16
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FIGURE 8. Simulated human plasma DEHP concentrations
during and after a 30-min infusion of 530 ml of pooled
72-hr-old platelet concentrate (90 mg DEHP total). The
simulation is based on average pharmacokinetic parameters
derived (21) from data reported on six patients receiving
DEHP-rich platelet concentrates (20), and assumes a body
surface are of 1.73 M2.
the possibility thattoxicity mayappearwith altered
DEHP metabolism or excretion due to hepatic or
renal disease.
There is no evidence at present that humans
exposed to DEHP via DEHP-laden blood products
or from other sources experience any adverse
effects from DEHP exposure. The studies ofDEHP
disposition reviewed in this paper demonstrate that
DEHP administered parenterally to primates and
humans is rapidly converted to conjugated hydro-
lyzed oxidation products of MEHP which are rap-
idly excreted in the urine. These metabolic pro-
cesses account for elimination of more than 50% of
the infused DEHP by 8 hr after infusion, while
elimination of the entire dose is virtually complete
in 4-5 days. Whether these dispositional events
account for the lack of observed human toxicity
from DEHP remains an unanswered question.
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